

Kyoichi Kaira

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/262341/kyoichi-kaira-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

246
papers

4,418
citations

34
h-index

53
g-index

266
ext. papers

5,334
ext. citations

3.8
avg. IF

5.15
L-index

#	Paper	IF	Citations
246	Visual Assessment of 18F-FDG Uptake on PET to Predict Survival Benefit to PD-1 Blockade in Non-Small Cell Lung Cancer.. <i>Clinical Nuclear Medicine</i> , 2022 , 47, 108-116	1.7	0
245	Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer.. <i>Scientific Reports</i> , 2022 , 12, 2742	4.9	2
244	Plasma plastin-3: A tumor marker in patients with non-small-cell lung cancer treated with nivolumab. <i>Oncology Letters</i> , 2021 , 21, 11	2.6	2
243	The Role of 18F-FDG-PET as Therapeutic Monitoring in Patients with Lung Cancer 2021 , 23-33		
242	Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers. <i>Frontiers in Oncology</i> , 2021 , 11, 610952	5.3	1
241	Synchronous dilemma of sarcoid-like reaction and drastic response after PD-1 blockade administration in lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021 , 51, 1179-1180	2.8	1
240	Post-Progression Survival Is Strongly Associated with Overall Survival in Patients Exhibiting Postoperative Relapse of Non-Small-Cell Lung Cancer Harboring Sensitizing Mutations. <i>Medicina (Lithuania)</i> , 2021 , 57,	3.1	1
239	Incidence and risk factors for pneumonitis among patients with lung cancer who received immune checkpoint inhibitors after palliative thoracic radiotherapy. <i>Journal of Radiation Research</i> , 2021 , 62, 669-675	2.4	1
238	Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression $\geq 50\%$ on first-line pembrolizumab. <i>Thoracic Cancer</i> , 2021 , 12, 304-313	3.2	6
237	Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer in comparison with chemoradiotherapy alone. <i>Thoracic Cancer</i> , 2021 , 12, 245-250	3.2	4
236	Detection of pseudoprogression with [F]-FDG-PET in a patient with pulmonary large cell neuroendocrine carcinoma who received anti-PD-1 treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 1268-1270	8.8	1
235	Post-Progression Survival Influences Overall Survival among Patients with Advanced Non-Small Cell Lung Cancer Undergoing First-Line Pembrolizumab Monotherapy. <i>Oncology</i> , 2021 , 99, 562-570	3.6	2
234	Expression of LAT1 and 4F2hc in Gastroenteropancreatic Neuroendocrine Neoplasms. <i>In Vivo</i> , 2021 , 35, 2425-2432	2.3	4
233	A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study). <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 1758835921998588	5.4	2
232	Effectiveness of EGFR-TKI rechallenge immediately after PD-1 blockade failure. <i>Thoracic Cancer</i> , 2021 , 12, 864-873	3.2	4
231	Clinical impact of post-progression survival on overall survival in patients receiving nivolumab monotherapy as a second-line treatment for advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021 , 12, 1171-1179	3.2	1
230	Feasibility of intensity modulated radiotherapy with involved field radiotherapy for Japanese patients with locally advanced non-small cell lung cancer. <i>Journal of Radiation Research</i> , 2021 , 62, 894-900	2.4	0

229	Comprehensive expressional analysis of chemosensitivity-related markers in large cell neuroendocrine carcinoma of the lung. <i>Thoracic Cancer</i> , 2021 , 12, 2666-2679	3.2	3
228	Tumor immunity is related to F-FDG uptake in thymic epithelial tumor. <i>Cancer Medicine</i> , 2021 , 10, 6317-6326	4.8	2
227	Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer. <i>Cancer Medicine</i> , 2021 , 10, 6971-6984	4.8	3
226	Combination of immune check inhibitor and immunomodulatory arabinomannan extracted from : A case report. <i>Molecular and Clinical Oncology</i> , 2021 , 15, 227	1.6	0
225	A 54Gy in three fractions of stereotactic body radiotherapy using CyberKnife for T1b-2aN0M0 pathologically confirmed non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021 , 51, 1723-1728	3.8	2
224	Course of postoperative relapse in non-small cell lung cancer is strongly associated with post-progression survival. <i>Thoracic Cancer</i> , 2021 , 12, 2740-2748	3.2	1
223	Value of F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers. <i>Cancer Imaging</i> , 2021 , 21, 11	5.6	6
222	Efficacy and Safety of Anti-Programed Death-1 Blockade in Previously Treated Large-Cell Neuroendocrine Carcinoma. <i>Chemotherapy</i> , 2021 , 66, 65-71	3.2	1
221	Management of Lung Cancer-Associated Malignant Pericardial Effusion with Intrapericardial Administration of Carboplatin: A Retrospective Study.. <i>Current Oncology</i> , 2021 , 29, 163-172	2.8	1
220	Occurrence of Hematological Malignancy in Long-term Survivors With Advanced Thymic Cancer. <i>In Vivo</i> , 2020 , 34, 1511-1513	2.3	0
219	Pattern of Local Failure and its Risk Factors of Locally Advanced Non-small Cell Lung Cancer Treated With Concurrent Chemo-radiotherapy. <i>Anticancer Research</i> , 2020 , 40, 3513-3517	2.3	3
218	Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer. <i>Clinical and Translational Radiation Oncology</i> , 2020 , 23, 85-88	4.6	11
217	Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment. <i>Thoracic Cancer</i> , 2020 , 11, 2188-2195	3.2	8
216	Prognostic significance of α -adrenergic receptor expression in patients with surgically resected colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2020 , 25, 1137-1144	4.2	4
215	Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: Management of adverse events. <i>Thoracic Cancer</i> , 2020 , 11, 1280-1287	3.2	13
214	Verrucous skin lesion caused by neuropathy misdiagnosed as squamous cell carcinoma and treated with amputation surgery. <i>Journal of Dermatology</i> , 2020 , 47, e188-e190	1.6	
213	Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 85, 761-771	3.5	19
212	Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	20

211	Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review. <i>In Vivo</i> , 2020 , 34, 877-880	2.3	6
210	Prognostic Significance of Glucose Metabolism as GLUT1 in Patients with Pulmonary Pleomorphic Carcinoma. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	3
209	Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer. <i>Medicine (United States)</i> , 2020 , 99, e19059	1.8	17
208	Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non-small cell lung cancer harboring EGFR mutation. <i>Thoracic Cancer</i> , 2020 , 11, 1045-1051	3.2	5
207	Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study. <i>Oncologist</i> , 2020 , 25, e668-e674	5.7	7
206	Administration of docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte colony-stimulating factor for pretreated non-small cell lung cancer: a phase II study. <i>Supportive Care in Cancer</i> , 2020 , 28, 4825-4831	3.9	3
205	FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020 , 181, 331-338	4.4	13
204	Diagnostic value of F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8 tumour-infiltrating lymphocytes in oral squamous cell carcinoma. <i>British Journal of Cancer</i> , 2020 , 122, 1686-1694	8.7	18
203	Uptake of positron emission tomography tracers reflects the tumor immune status in esophageal squamous cell carcinoma. <i>Cancer Science</i> , 2020 , 111, 1969-1978	6.9	6
202	Distinctive roles of syntaxin binding protein 4 and its action target, TP63, in lung squamous cell carcinoma: a theranostic study for the precision medicine. <i>BMC Cancer</i> , 2020 , 20, 935	4.8	4
201	Interstitial lung disease secondary to alectinib after interstitial injury induced by crizotinib. <i>Journal of Cancer Research and Therapeutics</i> , 2020 , 16, 919-921	1.2	1
200	Prognostic Significance of Tumor Immunity in Surgically Resected Pulmonary Pleomorphic Carcinoma. <i>Anticancer Research</i> , 2020 , 40, 261-269	2.3	3
199	Efficacy of PD-1 blockade therapy and T cell immunity in lung cancer patients. <i>Immunological Medicine</i> , 2020 , 43, 10-15	3.7	2
198	Clinical significance of topoisomerase-II expression in patients with advanced non-small cell lung cancer treated with amrubicin. <i>Thoracic Cancer</i> , 2020 , 11, 426-435	3.2	3
197	Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 457-466	4.9	10
196	Relationship Between Tumor Immune Markers and Fluorine-18-[Methyltyrosine ([F]FAMT) Uptake in Patients with Lung Cancer. <i>Molecular Imaging and Biology</i> , 2020 , 22, 1078-1086	3.8	3
195	Pseudoprogression mimicking hyperprogressive disease after pembrolizumab treatment in a patient with lung cancer. <i>Lung Cancer</i> , 2020 , 139, 221-223	5.9	1
194	CD4 T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy. <i>Cancer Immunology Research</i> , 2020 , 8, 334-344	12.5	68

193	Osimertinib induced cardiomyopathy: A case report. <i>Medicine (United States)</i> , 2020 , 99, e22301	1.8	4
192	Stereotactic body radiation therapy using CyberKnife for T1N0M0 lung cancer patients with severe pulmonary dysfunction. <i>Journal of Radiation Research</i> , 2020 , 61, 903-907	2.4	2
191	Prognostic value of morphological characteristics assessed by CT scan in patients with non-small cell lung cancer treated with nivolumab. <i>Thoracic Cancer</i> , 2020 , 11, 3521-3527	3.2	1
190	A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress). <i>BMC Cancer</i> , 2020 , 20, 961	4.8	1
189	Primary thymic adenocarcinoma with an aggressive clinical course: An autopsy case showing signet ring cell-like features. <i>Thoracic Cancer</i> , 2020 , 11, 3609-3613	3.2	1
188	Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer. <i>Chemotherapy</i> , 2020 , 65, 21-28	3.2	2
187	Occurrence of Ventricular Fibrillation in a Patient With Lung Cancer Receiving Osimertinib. <i>Journal of Thoracic Oncology</i> , 2020 , 15, e54-e55	8.9	1
186	Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged ≥5 years) with non-small cell lung cancer: A retrospective analysis. <i>Thoracic Cancer</i> , 2020 , 11, 2867-2876	3.2	2
185	Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. <i>Nature Communications</i> , 2020 , 11, 4607	17.4	31
184	Tumor metabolic volume by F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ^{MS} . <i>Scientific Reports</i> , 2020 , 10, 14990	4.9	6
183	Severe gastritis due to pembrolizumab treatment in a lung cancer patient. <i>Respirology Case Reports</i> , 2020 , 8, e00636	0.9	1
182	Recovery of the Sensitivity to Anti-PD-1 Antibody by Celecoxib in Lung Cancer. <i>Anticancer Research</i> , 2020 , 40, 5309-5311	2.3	2
181	High Stromal TGFBI in Lung Cancer and Intratumoral CD8-Positive T Cells were Associated with Poor Prognosis and Therapeutic Resistance to Immune Checkpoint Inhibitors. <i>Annals of Surgical Oncology</i> , 2020 , 27, 933-942	3.1	13
180	Prospective Feasibility Study of Amrubicin and Bevacizumab Therapy for Patients With Previously Treated Advanced NSCLC. <i>Anticancer Research</i> , 2020 , 40, 1571-1578	2.3	
179	Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors. <i>Thoracic Cancer</i> , 2019 , 10, 2200-2208	3.2	5
178	Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 84, 873-880	3.5	18
177	Pirfenidone Improves Familial Idiopathic Pulmonary Fibrosis without Affecting Serum Periostin Levels. <i>Medicina (Lithuania)</i> , 2019 , 55,	3.1	2
176	Clinical and Biological Significance of PD-L1 Expression Within the Tumor Microenvironment of Oral Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2019 , 39, 3039-3046	2.3	16

175	Drastic Response of Re-challenge of EGFR-TKIs Immediately After Nivolumab Therapy in EGFR-TKI-Resistant Patients. <i>Journal of Thoracic Oncology</i> , 2019 , 14, e135-e136	8.9	5
174	Fluorodeoxyglucose uptake is associated with low tumor-infiltrating lymphocyte levels in patients with small cell lung cancer. <i>Lung Cancer</i> , 2019 , 134, 180-186	5.9	11
173	Role of Amino Acid Transporter Expression as a Prognostic Marker in Patients With Surgically Resected Colorectal Cancer. <i>Anticancer Research</i> , 2019 , 39, 2535-2543	2.3	15
172	An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2019 , 39, 2483-2491	2.3	3
171	Dual inhibition of MEK and p38 impairs tumor growth in -mutated non-small cell lung cancer. <i>Oncology Letters</i> , 2019 , 17, 3569-3575	2.6	5
170	Radiotherapy is an independent prognostic marker of favorable prognosis in non-small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab. <i>Thoracic Cancer</i> , 2019 , 10, 992-1000	3.2	30
169	Post-treatment Glasgow Prognostic Score Predicts Efficacy in Advanced Non-small-cell Lung Cancer Treated With Anti-PD1. <i>Anticancer Research</i> , 2019 , 39, 1455-1461	2.3	18
168	Spontaneous aspiration of a long tree twig as foreign body. <i>Respirology Case Reports</i> , 2019 , 7, e00401	0.9	
167	Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer. <i>Thoracic Cancer</i> , 2019 , 10, 975-979	3.2	16
166	Clinical significance of primary prophylactic pegylated-granulocyte-colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019 , 10, 1005-1008	3.2	4
165	Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 84, 655-660	3.5	4
164	βAdrenergic receptor expression is associated with biomarkers of tumor immunity and predicts poor prognosis in estrogen receptor-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019 , 177, 603-610	4.4	12
163	Stathmin-1 Is a Useful Diagnostic Marker for High-Grade Lung Neuroendocrine Tumors. <i>Annals of Thoracic Surgery</i> , 2019 , 108, 235-243	2.7	3
162	Fucosylated βacid glycoprotein as a biomarker to predict prognosis following tumor immunotherapy of patients with lung cancer. <i>Scientific Reports</i> , 2019 , 9, 14503	4.9	7
161	Clinical Significance of Various Drug-Sensitivity Markers in Patients with Surgically Resected Pulmonary Pleomorphic Carcinoma. <i>Cancers</i> , 2019 , 11,	6.6	3
160	Carbonic anhydrase 9 expression is associated with poor prognosis, tumor proliferation, and radiosensitivity of thymic carcinomas. <i>Oncotarget</i> , 2019 , 10, 1306-1319	3.3	2
159	Treatment with Tumor Necrosis Factor-βInhibitors, History of Allergy, and Hypercalcemia Are Risk Factors of Immune Reconstitution Inflammatory Syndrome in HIV-Negative Pulmonary Tuberculosis Patients. <i>Journal of Clinical Medicine</i> , 2019 , 9,	5.1	2
158	Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients. <i>Thoracic Cancer</i> , 2019 , 10, 775-781	3.2	38

157	Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 83, 817-825	3.5	4
156	Prognostic Impact of α Adrenergic Receptor Expression in Surgically Resected Pulmonary Pleomorphic Carcinoma. <i>Anticancer Research</i> , 2019 , 39, 395-403	2.3	9
155	Expression of amino acid transporter (LAT1 and 4F2hc) in pulmonary pleomorphic carcinoma. <i>Human Pathology</i> , 2019 , 84, 142-149	3.7	22
154	High expression of carcinoembryonic antigen and telomerase reverse transcriptase in circulating tumor cells is associated with poor clinical response to the immune checkpoint inhibitor nivolumab. <i>Oncology Letters</i> , 2018 , 15, 3061-3067	2.6	8
153	The effect of post-progression survival on overall survival among patients with sensitive relapse of small cell lung cancer. <i>Medical Oncology</i> , 2018 , 35, 45	3.7	2
152	High expression of topoisomerase-II predicts favorable clinical outcomes in patients with relapsed small cell lung cancers receiving amrubicin. <i>Lung Cancer</i> , 2018 , 115, 42-48	5.9	7
151	A new enzyme immunoassay for the determination of highly sialylated and fucosylated human Acid glycoprotein as a biomarker of tumorigenesis. <i>Clinica Chimica Acta</i> , 2018 , 478, 120-128	6.2	9
150	Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma. <i>Lung Cancer</i> , 2018 , 119, 71-77	5.9	31
149	Sodium Glucose Cotransporter 2 Inhibition Combined With Cetuximab Significantly Reduced Tumor Size and Carcinoembryonic Antigen Level in Colon Cancer Metastatic to Liver. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e45-e48	3.8	10
148	Metabolic activity by F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 56-66	8.8	124
147	2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma. <i>European Journal of Cancer</i> , 2018 , 101, 181-190	7.5	51
146	Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 82, 119-127	3.5	2
145	Reply to: Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 82, 369	3.5	
144	Prognostic significance of PD-L1 expression and tumor infiltrating lymphocytes in large cell neuroendocrine carcinoma of lung. <i>American Journal of Translational Research (discontinued)</i> , 2018 , 10, 3243-3253	3	13
143	Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 81, 141-153	3.5	32
142	Accumulation of periostin in acute exacerbation of familial idiopathic pulmonary fibrosis. <i>Journal of Thoracic Disease</i> , 2018 , 10, E587-E591	2.6	9
141	Prognostic value of metabolic tumor volume of pretreatment F-FAMT PET/CT in non-small cell lung Cancer. <i>BMC Medical Imaging</i> , 2018 , 18, 46	2.9	5
140	Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis. <i>Thoracic Cancer</i> , 2018 , 9, 1699-1706	3.2	3

139	A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations. <i>Lung Cancer</i> , 2018 , 126, 41-47	5.9	21
138	STXBP4 Drives Tumor Growth and Is Associated with Poor Prognosis through PDGF Receptor Signaling in Lung Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017 , 23, 3442-3452	12.9	12
137	Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 79, 165-171	3.5	9
136	High stathmin expression is associated with poor prognosis and chemoradiation resistance in esophageal squamous cell carcinoma. <i>International Journal of Oncology</i> , 2017 , 50, 1184-1190	4.4	9
135	Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy. <i>Chemotherapy</i> , 2017 , 62, 205-213	3.2	8
134	Clinical significance of post-progression survival in lung cancer. <i>Thoracic Cancer</i> , 2017 , 8, 379-386	3.2	35
133	Caspase14 expression is associated with triple negative phenotypes and cancer stem cell marker expression in breast cancer patients. <i>Journal of Surgical Oncology</i> , 2017 , 116, 706-715	2.8	11
132	High expression of GRP78/BiP as a novel predictor of favorable outcomes in patients with advanced thymic carcinoma. <i>International Journal of Clinical Oncology</i> , 2017 , 22, 872-879	4.2	6
131	High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancer patients. <i>British Journal of Cancer</i> , 2017 , 116, 1177-1185	8.7	33
130	Successful afatinib treatment of advanced non-small-cell lung cancer patients undergoing hemodialysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 79, 209-213	3.5	6
129	Positive PD-L1 Expression Predicts Worse Outcome in Cutaneous Angiosarcoma. <i>Journal of Global Oncology</i> , 2017 , 3, 360-369	2.6	25
128	High STMN1 Expression is Associated with Cancer Progression and Chemo-Resistance in Lung Squamous Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2017 , 24, 4017-4024	3.1	12
127	High expression of nucleobindin 2 is associated with poor prognosis in gastric cancer. <i>Tumor Biology</i> , 2017 , 39, 1010428317703817	2.9	3
126	A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 615-622	3.5	9
125	Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 79, 497-505	3.5	15
124	Prospective exploratory study of gemcitabine and S-1 against elderly patients with advanced non-small cell lung cancer. <i>Oncology Letters</i> , 2017 , 14, 1123-1128	2.6	2
123	Clinical and Pathological Significance of ER Stress Marker (BiP/GRP78 and PERK) Expression in Malignant Melanoma. <i>Pathology and Oncology Research</i> , 2017 , 23, 111-116	2.6	24
122	Prognostic role of BiP/GRP78 expression as ER stress in patients with gastric adenocarcinoma. <i>Cancer Biomarkers</i> , 2017 , 20, 273-281	3.8	12

121	Prognostic effect of class III β -tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors. <i>Oncology Letters</i> , 2017 , 14, 2369-2378	2.6	4
120	Prognostic Significance of the Expression of CD98 (4F2hc) in Gastric Cancer. <i>Anticancer Research</i> , 2017 , 37, 631-636	2.3	7
119	Clinical Significance and Phenotype of MTA1 Expression in Esophageal Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2017 , 37, 4147-4155	2.3	6
118	PET-CT, Bio-imaging for Predicting Prognosis and Response to Chemotherapy in Patients with Lung Cancer 2017 , 45-61		
117	Expression of ER stress markers (GRP78/BiP and PERK) in adenoid cystic carcinoma. <i>Acta Oto-Laryngologica</i> , 2016 , 136, 1-7	1.6	15
116	Efficacy of system l amino acid transporter 1 inhibition as a therapeutic target in esophageal squamous cell carcinoma. <i>Cancer Science</i> , 2016 , 107, 1499-1505	6.9	28
115	Transport of 3-fluoro-L- β -methyl-tyrosine (FAMT) by organic ion transporters explains renal background in [(18)F]FAMT positron emission tomography. <i>Journal of Pharmacological Sciences</i> , 2016 , 130, 101-9	3.7	14
114	Clinicopathological significance of LAT1 and ASCT2 in patients with surgically resected esophageal squamous cell carcinoma. <i>Journal of Surgical Oncology</i> , 2016 , 113, 381-9	2.8	32
113	Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2016 , 21, 240-247	4.2	3
112	Prognostic significance of α -adrenergic receptor expression in malignant melanoma. <i>Tumor Biology</i> , 2016 , 37, 5971-8	2.9	10
111	Prognostic significance of α -adrenergic receptor expression in non-small cell lung cancer. <i>American Journal of Translational Research (discontinued)</i> , 2016 , 8, 5059-5070	3	15
110	Usefulness of 18F- β -Methyltyrosine PET for Therapeutic Monitoring of Patients with Advanced Lung Cancer. <i>Anticancer Research</i> , 2016 , 36, 6481-6490	2.3	5
109	Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide. <i>Canadian Respiratory Journal</i> , 2016 , 2016, 5405810	2.1	11
108	Decreased expression of class III β -tubulin is associated with unfavourable prognosis in patients with malignant melanoma. <i>Melanoma Research</i> , 2016 , 26, 29-34	3.3	12
107	Decreasing expression of glucose-regulated protein GRP78/BiP as a significant prognostic predictor in patients with advanced laryngeal squamous cell carcinoma. <i>Head and Neck</i> , 2016 , 38, 1539-44	4.2	11
106	Clinical significance of α -adrenergic receptor expression in patients with surgically resected gastric adenocarcinoma. <i>Tumor Biology</i> , 2016 , 37, 13885-13892	2.9	13
105	Specific transport of 3-fluoro-L- β -methyl-tyrosine by LAT1 explains its specificity to malignant tumors in imaging. <i>Cancer Science</i> , 2016 , 107, 347-52	6.9	24
104	(18)F-FDG uptake on PET correlates with biological potential in early oral squamous cell carcinoma. <i>Acta Oto-Laryngologica</i> , 2015 , 135, 494-9	1.6	16

103	The efficacy of amrubicin on central nervous system metastases originating from small-cell lung cancer: a case series of eight patients. <i>Investigational New Drugs</i> , 2015 , 33, 755-60	4.3	5
102	First-line gefitinib treatment in elderly patients (aged ≥ 5 years) with non-small cell lung cancer harboring EGFR mutations. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 76, 761-9	3.5	14
101	Clinicopathological significance of ASC amino acid transporter-2 expression in pancreatic ductal carcinoma. <i>Histopathology</i> , 2015 , 66, 234-43	7.3	26
100	Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer. <i>BMC Cancer</i> , 2015 , 15, 989	4.8	25
99	CD98 as a novel prognostic indicator for patients with stage III/IV hypopharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2015 , 37, 1569-74	4.2	16
98	Expression of amino acid transporters (LAT1, ASCT2 and xCT) as clinical significance in hepatocellular carcinoma. <i>Hepatology Research</i> , 2015 , 45, 1014-1022	5.1	36
97	Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in cutaneous melanoma. <i>Melanoma Research</i> , 2015 , 25, 399-405	3.3	42
96	Expression of Amino Acid Transporters (LAT1 and ASCT2) in Patients with Stage III/IV Laryngeal Squamous Cell Carcinoma. <i>Pathology and Oncology Research</i> , 2015 , 21, 1175-81	2.6	28
95	Recurrent intimal sarcoma mimicking pulmonary embolism. <i>Japanese Journal of Clinical Oncology</i> , 2015 , 45, 695-6	2.8	1
94	Relationship between CD147 and expression of amino acid transporters (LAT1 and ASCT2) in patients with pancreatic cancer. <i>American Journal of Translational Research (discontinued)</i> , 2015 , 7, 356-63	3	14
93	Clinical significance of coexpression of L-type amino acid transporter 1 (LAT1) and ASC amino acid transporter 2 (ASCT2) in lung adenocarcinoma. <i>American Journal of Translational Research (discontinued)</i> , 2015 , 7, 1126-39	3	19
92	Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in patients with ovarian tumors. <i>American Journal of Translational Research (discontinued)</i> , 2015 , 7, 1161-71	3	23
91	Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer. <i>Annals of Thoracic Medicine</i> , 2015 , 10, 61-6	2.2	26
90	Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer. <i>Lung Cancer</i> , 2014 , 83, 197-204	5.9	74
89	Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy. <i>Medical Oncology</i> , 2014 , 31, 88	3.7	13
88	Small-cell lung cancer with voltage-gated calcium channel antibody-positive paraneoplastic limbic encephalitis: a case report. <i>Journal of Medical Case Reports</i> , 2014 , 8, 119	1.2	8
87	18 F-FDG uptake on PET is a predictive marker of thymidylate synthase expression in patients with thoracic neoplasms. <i>Oncology Reports</i> , 2014 , 31, 209-15	3.5	5
86	Dramatic Response of S-1 Administration to Chemorefractory Advanced Thymic Cancer. <i>Chemotherapy</i> , 2014 , 60, 356-9	3.2	2

85	Surrogate endpoints for overall survival in advanced non-small-cell lung cancer patients with mutations of the epidermal growth factor receptor gene. <i>Molecular and Clinical Oncology</i> , 2014 , 2, 731-736	1.6	18
84	CD98 is a promising prognostic biomarker in biliary tract cancer. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2014 , 13, 654-7	2.1	11
83	Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma. <i>Cancer Science</i> , 2014 , 105, 1496-502	6.9	38
82	Prognostic impact of 18F-FDG uptake on PET in non-small cell lung cancer patients with postoperative recurrence following platinum-based chemotherapy. <i>Respiratory Investigation</i> , 2014 , 52, 121-8	3.4	4
81	Biological evaluation of 3-[(18)F]fluoro-β-methyl-D-tyrosine (D-[(18)F]FAMT) as a novel amino acid tracer for positron emission tomography. <i>Annals of Nuclear Medicine</i> , 2013 , 27, 314-24	2.5	16
80	Clinicopathological significance of L-type amino acid transporter 1 (LAT1) expression in patients with adenoid cystic carcinoma. <i>Pathology and Oncology Research</i> , 2013 , 19, 649-56	2.6	14
79	The role of β-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy. <i>International Journal of Clinical Oncology</i> , 2013 , 18, 371-9	4.2	24
78	Diagnostic usefulness of β-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013 , 40, 1692-700	8.8	30
77	Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2013 , 82, 449-54	5.9	18
76	Phase II study of oral S-1 plus cisplatin with bevacizumab for advanced non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2013 , 82, 103-8	5.9	6
75	Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent S-1 and cisplatin for inoperable stage III non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2013 , 14, 440-5	4.9	12
74	Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer. <i>BMC Cancer</i> , 2013 , 13, 482	4.8	65
73	Biological correlation of β-FDG uptake on PET in pulmonary neuroendocrine tumors. <i>Anticancer Research</i> , 2013 , 33, 4219-28	2.3	19
72	Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma. <i>European Journal of Cancer</i> , 2012 , 48, 1244-54	7.5	38
71	18F-FDG uptake on PET in primary mediastinal non-thymic neoplasm: a clinicopathological study. <i>European Journal of Radiology</i> , 2012 , 81, 2423-9	4.7	15
70	Thymidylate synthase expression is closely associated with outcome in patients with pulmonary adenocarcinoma. <i>Medical Oncology</i> , 2012 , 29, 1663-72	3.7	24
69	β-FAMT in patients with multiple myeloma: clinical utility compared to β-FDG. <i>Annals of Nuclear Medicine</i> , 2012 , 26, 811-6	2.5	18
68	β-FDG uptake on PET could be a predictive marker of excision repair cross-complementation group 1 (ERCC1) expression in patients with thoracic neoplasms?. <i>Neoplasma</i> , 2012 , 59, 257-63	3.3	4

67	MUC1 expression in pulmonary metastatic tumors: a comparison of primary lung cancer. <i>Pathology and Oncology Research</i> , 2012 , 18, 439-47	2.6	9
66	Transport of 3-fluoro-L-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET. <i>Journal of Nuclear Medicine</i> , 2012 , 53, 1253-61	8.9	95
65	Depolarized MUC1 expression is closely associated with hypoxic markers and poor outcome in resected non-small cell lung cancer. <i>International Journal of Surgical Pathology</i> , 2012 , 20, 223-32	1.2	18
64	Biologic correlates of 18 F-FDG uptake on PET in pulmonary pleomorphic carcinoma. <i>Lung Cancer</i> , 2011 , 71, 144-50	5.9	33
63	Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors. <i>Lung Cancer</i> , 2011 , 74, 419-25	5.9	18
62	The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1242-6	8.9	127
61	Expression of 4F2hc (CD98) in pulmonary neuroendocrine tumors. <i>Oncology Reports</i> , 2011 , 26, 931-7	3.5	17
60	Expression of excision repair cross-complementation group 1, breast cancer susceptibility 1, and β -III-tubulin in thymic epithelial tumors. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 606-13	8.9	13
59	Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. <i>Cancer Science</i> , 2011 , 102, 1032-7	6.9	99
58	MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011 , 458, 615-20	5.1	18
57	18 F-FDG uptake on PET helps predict outcome and response after treatment in unresectable thymic epithelial tumors. <i>Annals of Nuclear Medicine</i> , 2011 , 25, 247-53	2.5	23
56	Correlation between 18 F-FDG uptake on PET and molecular biology in metastatic pulmonary tumors. <i>Journal of Nuclear Medicine</i> , 2011 , 52, 705-11	8.9	43
55	A systemic review of PET and biology in lung cancer. <i>American Journal of Translational Research (discontinued)</i> , 2011 , 3, 383-91	3	16
54	LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer. <i>American Journal of Translational Research (discontinued)</i> , 2011 , 3, 468-78	3	49
53	The role of [18 F]fluorodeoxyglucose positron emission tomography in thymic epithelial tumors. <i>Cancer Imaging</i> , 2011 , 11, 195-201	5.6	16
52	Prognostic significance of thymidylate synthase expression in the adjuvant chemotherapy after resection for pulmonary metastases from colorectal cancer. <i>Anticancer Research</i> , 2011 , 31, 2763-71	2.3	9
51	Relationship between LAT1 expression and response to platinum-based chemotherapy in non-small cell lung cancer patients with postoperative recurrence. <i>Anticancer Research</i> , 2011 , 31, 3775-82	2.3	15
50	L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma. <i>Anticancer Research</i> , 2011 , 31, 4075-82	2.3	30

49	Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in surgically resectable stage III non-small cell lung cancer. <i>Experimental and Therapeutic Medicine</i> , 2010 , 1, 799-808	2.1	25
48	Prognostic and predictive factors in resected non-small-cell lung cancer. <i>Expert Opinion on Medical Diagnostics</i> , 2010 , 4, 373-81		7
47	Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3746-53	2.2	123
46	Assessment of therapy response in lung cancer with ^{18}F - β -methyl tyrosine PET. <i>American Journal of Roentgenology</i> , 2010 , 195, 1204-11	5.4	14
45	Long-term survivors of more than 5 years in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2010 , 67, 120-3	5.9	33
44	Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma. <i>Lung Cancer</i> , 2010 , 67, 194-7	5.9	65
43	Phase 2 study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2010 , 68, 253-7	5.9	10
42	A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer. <i>Lung Cancer</i> , 2010 , 69, 99-104	5.9	41
41	Comparison of L-type amino acid transporter 1 expression and L-[3-18F]- β -methyl tyrosine uptake in outcome of non-small cell lung cancer. <i>Nuclear Medicine and Biology</i> , 2010 , 37, 911-6	2.1	22
40	Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer. <i>Lung Cancer</i> , 2010 , 68, 99-104	5.9	46
39	Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 460-5	8.9	95
38	Pulmonary Pleomorphic Carcinoma: Diagnosis Using Small Biopsy Specimens. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 1492-1493	8.9	
37	Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer. <i>Annals of Nuclear Medicine</i> , 2010 , 24, 697-705	2.5	12
36	High-grade neuroendocrine carcinoma of the lung shows increased thymidylate synthase expression compared to other histotypes. <i>Journal of Surgical Oncology</i> , 2010 , 102, 11-7	2.8	14
35	CD98 expression is associated with the grade of malignancy in thymic epithelial tumors. <i>Oncology Reports</i> , 2010 , 24, 861-7	3.5	12
34	L-type amino-acid transporter 1 expression predicts the response to preoperative hyperthermo-chemoradiotherapy for advanced rectal cancer. <i>Anticancer Research</i> , 2010 , 30, 4223-7	2.3	19
33	Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer. <i>Anticancer Research</i> , 2010 , 30, 4819-28	2.3	91
32	18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer. <i>Journal of Nuclear Medicine</i> , 2009 , 50, 1770-6	8.9	40

31	Evaluation of thoracic tumors with (18)F-FMT and (18)F-FDG PET-CT: a clinicopathological study. <i>International Journal of Cancer</i> , 2009 , 124, 1152-60	7.5	32
30	L-type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas. <i>Journal of Surgical Oncology</i> , 2009 , 99, 433-8	2.8	37
29	Thymic squamous cell carcinoma producing granulocyte colony-stimulating factor associated with a high serum level of interleukin 6. <i>International Journal of Clinical Oncology</i> , 2009 , 14, 534-6	4.2	4
28	Pulmonary traumatic pneumatocele and hematoma. <i>Japanese Journal of Radiology</i> , 2009 , 27, 100-2	2.9	11
27	L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer. <i>Histopathology</i> , 2009 , 54, 804-13	7.3	43
26	Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung. <i>Cancer Science</i> , 2009 , 100, 248-54	6.9	38
25	Correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in non-small cell lung cancer. <i>Cancer Science</i> , 2009 , 100, 753-8	6.9	46
24	Phase I study of oral S-1 plus Cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 75, 109-14	4	9
23	CD98 expression is associated with poor prognosis in resected non-small-cell lung cancer with lymph node metastases. <i>Annals of Surgical Oncology</i> , 2009 , 16, 3473-81	3.1	56
22	Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. <i>Lung Cancer</i> , 2009 , 66, 120-6	5.9	59
21	Forearm muscle metastasis as an initial clinical manifestation of lung cancer. <i>Southern Medical Journal</i> , 2009 , 102, 79-81	0.6	14
20	L-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. <i>Cancer Science</i> , 2008 , 99, 2380-6	6.9	105
19	Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. <i>Lung Cancer</i> , 2008 , 59, 203-10	5.9	113
18	Laryngeal sarcoidosis detected by FDG positron emission tomography. <i>Clinical Nuclear Medicine</i> , 2008 , 33, 878-9	1.7	11
17	B-cell non-Hodgkin lymphoma presenting as an endobronchial polypoid mass. <i>Journal of Thoracic Oncology</i> , 2008 , 3, 530-1	8.9	5
16	Primary mediastinal synovial sarcoma: a report of 2 cases. <i>Journal of Computer Assisted Tomography</i> , 2008 , 32, 238-41	2.2	6
15	Phase I trial of oral S-1 plus gemcitabine in elderly patients with nonsmall cell lung cancer. <i>Anti-Cancer Drugs</i> , 2008 , 19, 289-94	2.4	7
14	Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung. <i>Pathology Research and Practice</i> , 2008 , 204, 553-61	3.4	49

13	Rapid growth of malignant pleural mesothelioma. <i>Journal of Thoracic Oncology</i> , 2007 , 2, 966-7	8.9	4
12	Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. <i>Clinical Cancer Research</i> , 2007 , 13, 6369-78	12.9	90
11	A phase I dose-escalation study of S-1 plus carboplatin in patients with advanced non-small-cell lung cancer. <i>Anti-Cancer Drugs</i> , 2007 , 18, 471-6	2.4	12
10	A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007 , 30, 51-6	2.7	7
9	Value of FDG positron emission tomography in monitoring the effects of therapy in progressive pulmonary sarcoidosis. <i>Clinical Nuclear Medicine</i> , 2007 , 32, 114-6	1.7	19
8	Phase I study of biweekly paclitaxel and carboplatin for frail patients with advanced non-small cell lung cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007 , 30, 487-91	2.7	3
7	Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients. <i>Chest</i> , 2007 , 131, 1019-27	5.3	95
6	Small cell carcinoma of the parotid gland. <i>Otolaryngology - Head and Neck Surgery</i> , 2007 , 136, 330-1	5.5	2
5	Coinfection of invasive pulmonary aspergillosis and pneumocystis jiroveci pneumonia in a non-HIV patient. <i>Acta Medica Okayama</i> , 2007 , 61, 235-8	0.5	2
4	Fulminant hepatic failure resulting from small-cell lung cancer and dramatic response of chemotherapy. <i>World Journal of Gastroenterology</i> , 2006 , 12, 2466-8	5.6	16
3	Phase II study of weekly docetaxel and cisplatin in patients with non-small cell lung cancer. <i>Anti-Cancer Drugs</i> , 2005 , 16, 455-60	2.4	8
2	Management of malignant pericardial effusion with instillation of mitomycin C in non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2005 , 35, 57-60	2.8	17
1	Barium sulphate aspiration. <i>Lancet, The</i> , 2004 , 364, 2220	4.0	18